EMA CHMP Chair Re-elected
Tomas Salmonson is re-elected as Chair of the Committee for Medicinal Products for Human Use.
The European Medicines Agency (EMA) announced on Sept. 21, 2015 that Dr. Tomas Salmonson has been re-elected as Chair of the Committee for Medicinal Products for Human Use (CHMP). Salmonson is senior scientific advisor at the Swedish Medical Products Agency, has been a member of CHMP for more than 15 years, and has served as CHMP chair for the past three years.
According to an EMA press release, in his second term, Salmonson plans on deepening stakeholder collaboration, facilitating the development of and access to innovative medicines, and improving benefit-risk methodologies.
In response to his re-election, Salmonson stated, “It is a great honor for me to receive the backing of my peers for another term. I have a deep respect and appreciation for the work of the dedicated and professional members of the Committee. CHMP is a forum for open discussion. Debate between members with different backgrounds and views is an essential element in delivering robust scientific opinions. I look forward to working even harder to maintain and strengthen this fruitful working environment in order to fulfill our public health mandate.”
Source: European Medicines Agency
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
